{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:57:02Z","timestamp":1771459022203,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.intimp.2024.112958","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T17:53:33Z","timestamp":1724003613000},"page":"112958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prognostic impact of enhanced CD96 expression on NK cells by TGF-\u03b21 in AML"],"prefix":"10.1016","volume":"141","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luhua","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maohua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-3138","authenticated-orcid":false,"given":"Erxia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2024.112958_b0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112958_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-019-0170-3","article-title":"Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia","volume":"9","author":"Yilmaz","year":"2019","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.intimp.2024.112958_b0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadi\u00e9","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112958_b0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.intimp.2024.112958_b0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.14348\/molcells.2021.0078","article-title":"iPSC-derived natural killer cells for cancer immunotherapy","volume":"44","author":"Karagiannis","year":"2021","journal-title":"Mol. Cells"},{"issue":"2","key":"10.1016\/j.intimp.2024.112958_b0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1539617","article-title":"Acute myeloid leukemia and NK cells: two warriors confront each other","volume":"8","author":"Baraga\u00f1o Raneros","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.112958_b0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fimmu.2017.00573","article-title":"Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/icb.2011.15","article-title":"Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients","volume":"90","author":"Sanchez-Correa","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112958_b0055","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2019-128178","article-title":"Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.112958_b0060","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol. Rev."},{"issue":"39","key":"10.1016\/j.intimp.2024.112958_b0070","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","article-title":"Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option","volume":"37","author":"Stamm","year":"2018","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.intimp.2024.112958_b0075","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ni.2850","article-title":"The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions","volume":"15","author":"Chan","year":"2014","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112958_b0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-15-0944","article-title":"Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy","volume":"6","author":"Blake","year":"2016","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.intimp.2024.112958_b0085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1445949","article-title":"Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis","volume":"7","author":"Harjunp\u00e4\u00e4","year":"2018","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.intimp.2024.112958_b0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-18-0637","article-title":"CD96 is an immune checkpoint that regulates CD8(+) T-cell antitumor function","volume":"7","author":"Mittal","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.intimp.2024.112958_b0095","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.148.8.2600","article-title":"Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily","volume":"148","author":"Wang","year":"1992","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112958_b0100","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112958_b0105","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1074\/jbc.M807698200","article-title":"CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains","volume":"284","author":"Meyer","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2024.112958_b0110","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/0008-5472.CAN-06-2264","article-title":"DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells","volume":"67","author":"Carlsten","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2024.112958_b0115","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/eji.201948405","article-title":"CD96 functions as a co-stimulatory receptor to enhance CD8(+) T cell activation and effector responses","volume":"50","author":"Chiang","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep.30347","article-title":"Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma","volume":"70","author":"Sun","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0125","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41467-020-14802-2","article-title":"Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0130","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1002\/ajh.24925","article-title":"Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia","volume":"93","author":"Izzi","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112958_b0135","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.exphem.2009.07.009","article-title":"Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy","volume":"37","author":"Ayello","year":"2009","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112958_b0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00262-021-02978-5","article-title":"Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis","volume":"71","author":"Liu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2024.112958_b0145","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","article-title":"CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients","volume":"190","author":"Wang","year":"2018","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112958_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213482","article-title":"LRRC33 is a novel binding and potential regulating protein of TGF-\u03b21 function in human acute myeloid leukemia cells","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.intimp.2024.112958_b0155","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020459118","article-title":"High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome","volume":"118","author":"Chretien","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"42","key":"10.1016\/j.intimp.2024.112958_b0160","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"22","key":"10.1016\/j.intimp.2024.112958_b0165","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.3390\/ijms242216065","article-title":"CRISPR-Cas9-based gene knockout of immune checkpoints in expanded NK cells","volume":"24","author":"Mohammadian Gol","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.intimp.2024.112958_b0170","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","article-title":"Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy","volume":"22","author":"Blake","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.112958_b0175","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/ijms24021303","article-title":"CD96 as a potential immune regulator in cancers","volume":"24","author":"Feng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.intimp.2024.112958_b0180","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.intimp.2024.112958_b0185","doi-asserted-by":"crossref","first-page":"e24500","DOI":"10.4161\/onci.24500","article-title":"Strategies for purging CD96(+) stem cells in vitro and in vivo: new avenues for autologous stem cell transplantation in acute myeloid leukemia","volume":"2","author":"Staudinger","year":"2013","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0190","doi-asserted-by":"crossref","first-page":"14684","DOI":"10.1038\/s41598-017-14661-w","article-title":"Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia","volume":"7","author":"Hong","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2024.112958_b0195","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2010.039743","article-title":"Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1","volume":"96","author":"Szczepanski","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2024.112958_b0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fimmu.2014.00160","article-title":"Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia","volume":"5","author":"Hong","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112958_b0205","article-title":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.intimp.2024.112958_b0210","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-20-0575","article-title":"IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma","volume":"26","author":"Chauvin","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"415","key":"10.1016\/j.intimp.2024.112958_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"issue":"6958","key":"10.1016\/j.intimp.2024.112958_b0220","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112958_b0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112958_b0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-3083.1993.tb01667.x","article-title":"Regulation of natural killer cell activity by transforming growth factor-beta and prostaglandin E2","volume":"37","author":"Malygin","year":"1993","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2024.112958_b0235","doi-asserted-by":"crossref","first-page":"14677","DOI":"10.1038\/ncomms14677","article-title":"Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development","volume":"8","author":"Tang","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2024.112958_b0240","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.ymthe.2018.06.016","article-title":"Combination of asiatic acid and naringenin modulates NK cell anti-cancer immunity by rebalancing Smad3\/Smad7 signaling","volume":"26","author":"Lian","year":"2018","journal-title":"Mol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924014796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924014796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:36:25Z","timestamp":1731087385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924014796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"alternative-id":["S1567576924014796"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112958","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of enhanced CD96 expression on NK cells by TGF-\u03b21 in AML","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112958"}}